Testing karxt for thinking problems in alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of mild or moderate Alzheimer's disease (stage 4 or 5).
- Your score on a memory test (MMSE) must be between 12 and 22 at the start.
- You need a caregiver who spends at least 10 hours a week with you and can come to all study visits.
- If you take Alzheimer's medications like donepezil or memantine, you must have been on a steady dose for at least 12 weeks and agree to keep it the same.
- You should not have severe medical problems like liver disease, kidney problems, unstable heart issues, or a history of certain mental health conditions.
- You cannot have had certain anti-amyloid treatments for Alzheimer's in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.